ProQR Therapeutics (PRQR) Payables (2013 - 2025)

ProQR Therapeutics has disclosed Payables across 13 years of filings, most recently posting $346885.0 for Q4 2025.

• Payables for Q4 2025 came in at $346885.0, up 1928.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $346885.0 (up 1928.86% YoY), and the FY2025 annual result was $346885.0, up 1928.86% from the prior year.
• Payables came in at $346885.0 for Q4 2025 at ProQR Therapeutics, up from $17097.5 in the prior quarter.
• In the past five years, Payables ranged from a high of $5.7 million in Q4 2021 to a low of $331.71 in Q1 2021.
• The 5-year median for Payables is $373411.0 (2022), against an average of $872161.8.
• Across the five-year window, Payables plunged 99.95% in 2021 and soared 278695.49% in 2022, its largest moves.
• ProQR Therapeutics' Payables stood at $5.7 million in 2021, then tumbled by 92.95% to $399937.0 in 2022, then surged by 314.57% to $1.7 million in 2023, then slumped by 98.97% to $17097.5 in 2024, then surged by 1928.86% to $346885.0 in 2025.
• The last three Payables figures came in at $346885.0 (Q4 2025), $17097.5 (Q4 2024), and $1.7 million (Q4 2023), per Business Quant data.